Immunotherapy saves many lives – but could help even more people
One out of five patients with metastatic skin cancer can be cured with immunotherapy. But half of the patients with metastatic malignant melanoma are not helped by the new treatment. Researchers at the Sahlgrenska Cancer Center and on the Melanoma Team at Sahlgrenska University Hospital are working together in an attempt to understand why immunotherapy has such varied effects for different patients.
Jonas nilsson is professor, group leader and director of Sahlgrenska Cancer Center as well as the group leader of Sahlgrenska Translational Melanom Group (SATMEG), which brings together researchers and medical doctors who together conduct research on melanoma.
In order to find out what types of help the immune system of a given patient should receive through immunotherapy, they are developing personalized animal models (with which they are in the forefront internationally) and are starting clinical trials with patients.
Find out more in the research story at Akademiliv.